SCHEMBL5212147

SCHEMBL5212147

CCOP(=O)(Cc1ccc(NC(=O)CCc2oc(-n3ccnc3)nc2-c2ccc(Cl)cc2)cc1)OCC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.39
LMNA P02545 2/20 0.39
MEN1 O00255 1/20 0.39
GLA P06280 1/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39
CD38 P28907 1/20 0.37
ENTPD1 P49961 1/20 0.37
CHRM1 P11229 1/20 0.36
HTR2A P28223 1/20 0.36
MCHR1 Q99705 1/20 0.36
ENTPD2 Q9Y5L3 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
PORCN Q9H237 1/20 0.35
YES1 P07947 1/20 0.34
KDR P35968 1/20 0.34
JAK3 P52333 1/20 0.34
POLB P06746 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5210390 0.86 MAPT (0.41) MAPTLMNAMEN1GLAMAPK1
SCHEMBL5207021 0.85 MAPT (0.44) MAPTLMNAMEN1GLAMAPK1
SCHEMBL5214638 0.85 MAPT (0.41) MAPTLMNAMEN1GLAMAPK1
SCHEMBL5213780 0.85 MAPT (0.42) MAPTLMNAMEN1GLAMAPK1
SCHEMBL5211940 0.84 MAPT (0.45) MAPTLMNAMEN1GLAMAPK1
SCHEMBL5207465 0.83 MAPT (0.44) MAPTLMNAMEN1GLAMAPK1
SCHEMBL5207019 0.83 MAPT (0.39) MAPTLMNAMEN1GLAMAPK1
SCHEMBL5207380 0.83 LMNA (0.45) MAPTLMNAMEN1GLAMAPK1
SCHEMBL5212143 0.82 CD38 (0.37) MAPTLMNAMEN1GLAMAPK1
SCHEMBL5212800 0.82 MAPT (0.37) MAPTLMNAMEN1GLAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7183276-B2 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-27 US disclosed
US-20050090534-A1 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-28 US disclosed
EP-1486490-A1 AZOLE COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2004-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090534-A1 Azole compounds AHR, NR0B2, NR2C2 MAPT 3958/4885LMNA 4253/4885MEN1 1626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.